,131 For instance, a retrospective multi-center cohort study analyzed advanced lung cancer patients with BRAF mutations who received targeted therapy (vemurafenib, dabrafenib, and sorafenib), and the results showed that among six patients with non-V600E BRAF mutations, one patient (17%) with the BRAF G596V mutation experienced a partial response after treatment with vemurafenib.132. Here, BRAF is linked to lung carcinoma.